MedTrace Logo

Safety Study of Nicotinamide to Treat Alzheimer's Disease

NCT00580931 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-01-25

No results posted yet for this study

Summary

The purpose of this study is to determine whether nicotinamide, or vitamin B3, is safe and effective in the treatment of Alzheimer's disease.

Conditions

Interventions

DRUG

Nicotinamide

1500 mg twice a day for 6 months

DRUG

Enduramide placebo

1 tab twice a day

Sponsors & Collaborators

Principal Investigators

  • Steven S Schreiber, MD · Regents of the University of California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00580931 on ClinicalTrials.gov